A federal review of private Medicare plans suggests a correlation between rejecting rehabilitation claims and corporate profit, though experts warn more data is needed to prove causation.
WASHINGTON — A retrospective review published by the Department of Health and Human Services Office of Inspector General has identified a potential, though not definitively causal, relationship between private Medicare Advantage plans rejecting rehabilitation claims and those same companies retaining the funds for themselves.
While the observational analysis of tens of thousands of prior authorization requests showed a statistically significant increase in profit margins among insurers, authors of the report were quick to note the methodological limitations. Because the investigation relied on retrospective administrative data from major carriers rather than a randomized controlled trial, researchers stressed that it is too early to definitively conclude that withholding medical care allows financial institutions to keep the money they would have otherwise spent. Peer reviewers cautioned that unmeasured factors, such as the natural lifecycle of corporate revenue streams, may also play a role.
Although the preliminary data indicates that erecting automated barriers to nursing facility care is highly associated with robust quarterly earnings, we must be careful not to extrapolate these findings to the broader intent of the insurance industry.
The federal review also documented a high rate of what researchers termed "secondary approval phenomenon," instances where initial coverage denials were rapidly reversed if a patient managed to survive long enough to file an appeal. Analysts caution that this secondary approval rate, which occurred in the vast majority of appealed cases, introduces complex confounding variables into the profit-motive hypothesis. The high frequency of reversals suggests the initial rejections may simply be an idiopathic algorithmic reflex or a localized software inflammation, rather than a targeted financial intervention designed to exhaust elderly patients into abandoning their claims.
Until double-blind, placebo-controlled trials can be conducted in which insurance executives are explicitly asked if they enjoy maximizing shareholder value, experts advise seniors to interpret the findings with measured skepticism. Older adults requiring acute physical rehabilitation are encouraged to consult their primary care physician before concluding that their insurer is intentionally attempting to bleed them dry.